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ABSTRAK
Kanker paru merupakan penyakit yang merugikan di dunia dengan angka insidensi, mortalitas dan 
morbiditas yang tinggi khususnya di negara berkembang. Pengobatan konvensional menggunakan kemoterapi 
sitotoksik memiliki kelemahan seperti kemungkinan resistensi dan toksisitas dari obat. Perkembangan terbaru 
menunjukkan bahwa Tyrosine Kinase Inhibitor generasi pertama, Gefitinib dan Erlotinib dan Tyrosine Kinase 
Inhibitor generasi kedua terbaru, Afatinib, memiliki potensi untuk menjadi pilihan pengobatan kanker paru 
bukan sel kecil (non-small cell lung cancer) metastatik/ lanjut EGFR (Epidermal Growth Factor Receptor) 
mutasi positif. Obat ini bekerja melalui ikatan yang ireversibel pada EGFR sehingga dapat menginaktivasi 
reseptor tirosin kinase. Beberapa studi menunjukkan bahwa Afatinib lini pertama dapat memperlama masa bebas 
progresivitas penyakit dan kontrol terhadap penyakit, serta dapat menjadi alternatif bagi pasien yang intoleran 
terhadap Gefitinib dan erlotinib. Di Indonesia, era Jaminan Kesehatan Nasional (JKN) telah terlaksana dan 
JKN menanggung penuh pengobatan kanker, termasuk TKI generasi pertama, Gefitinib dan Erlotinib, terhadap 
pasien-pasien kanker paru bukan sel kecil EGFR mutasi positif di Rumah Sakit Umum Pusat Nasional Dr. Cipto 
Mangunkusumo. Afatinib sebagai salah satu TKI generasi kedua terbaru, bisa juga diberikan sebagai alternatif 
apabila telah ditanggung JKN di masa datang. Akan tetapi, penilaian juga perlu dilakukan khususnya untuk 
mengetahui efektivitas dan efek samping yang dapat muncul pada pasien-pasien di negara-negara berkembang.
Kata kunci: kanker paru bukan sel kecil metastasis/ lanjut, EGFR mutasi positif, Afatinib.
ABSTRACT
Lung cancer is a devastating disease with a high incidence, mortality and morbidity rate, especially in 
developing countries. Conventional treatment with cytotoxic chemotherapy has some limitations attributed 
to chemoresistance and toxicity. Recent advances have shown that first generation Tyrosine Kinase Inhibitor 
(TKI), Gefitinib and Erlotinib, and the newest available second generation Tyrosine Kinase Inhibitor (TKI), 
Afatinib, have the potential to be an option in the management of patients with epidermal growth factor receptor/ 
EGFR mutation positive advanced/ metastatic non-small cell lung cancer. Afatinib works by binding to EGFR 
irreversibly, thus inactivating the tyrosine kinase receptor. Some studies demostrated that Afatinib first-line may 
result in longer progression free survival (PFS) and better disease control, and as an alternative for patients who 
intolerance to Gefitinib or Erlotinib. In Indonesia, the era of National Health Insurance has been implemented 
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and National Health Insurance has covered treatment for cancer, including first generation TKIs, Gefitinib dan 
erlotinib, for patients with EGFR mutation positive advanced/ metastatic non-small cell lung cancer at Cipto 
Mangunkusumo National Hospital. Afatinib, as one of the newest available second generation TKI, may be 
given free of charge too as an alternative if the National Health Insurance will be covered in the future. Further 
research is needed to know the efficacy and adverse effects that may occur in patients from developing countries. 
Keywords: advanced/metastatic non small cell lung cancer, EGFR mutation, afatinib.
INTRODUCTION
Being the most common for decades, there 
were 1.8 million new cases of lung cancer in 
2012, forming 12.9% of all cancers. Among 
58% or 1.066 million cases occurred in less 
developed regions. In some developing countries 
such as Indonesia, lung cancer is on the top with 
25,322 new cases or 18.2% in 2012.1 Data from 
Dharmais National Cancer Center in Indonesia 
also showed that lung cancer was one of the 
top three most prevalent cancers in 2010-2013 
continuously with around 117 to 173 new cases.2 
In India, with a population of around 1.258 
billion population, lung cancer was also ranked 
the highest number of new cancer cases in 2012, 
with 53,728 people diagnosed.1
Besides its high incidence, lung cancer is 
also the deadliest cancer in the world causing 
21.9% of all cancer-related mortality. Focusing 
on developing countries, Indonesia and India 
also claimed lung cancer as the highest cause of 
cancer-related mortality, with 22,525 and 48,697 
fatal cases in 2012.2 Moreover, lung cancer had 
cost $12.1 billion to The U.S. health fund in 2010 
and loss of productivity due to early death.3 Thus, 
research has been done to find the best way of 
curing these diseases.
There are many treatment options for cancer 
management, however, traditional treatment 
such as chemotherapy, which rely on the 
histopathologic subtype has limited efficacy 
attributed to chemoresistance and toxicity 
(e.g. nausea and vomiting, alopecia, fatigue, 
cytopenias, febrile neutropenia, nerve, and kidney 
damage, as well as death).4 Recent advances have 
shown that understanding the basic molecular 
of cancer has led to a new paradigm in curing 
cancer, the era of personalized medicine. One 
of them is the development of Tyrosine Kinase 
Inhibitors (TKIs) as targeted therapies in cancer 
management. This review will explore more on 
the role of TKIs especially Afatinib as the newest 
available targeted therapy in Non-Small Cell 
Lung Cancer (NSCLC) management and what 
can be learned for developing country.5
LUNG CANCER
Lung cancer is divided into two main 
histological subtypes, Small Cell Lung Cancer 
and Non Small Cell Lung Cancer (NSCLC). 
The latter is further classified into three major 
histologic subtypes, squamous-cell carcinoma 
with keratin expression, adenocarcinoma with 
glandular expression, and large-cell carcinoma. 
Among those types of cancer, NSCLC (86%) 
with  adenocarcinoma and squamous cell 
carcinoma is the most common subtype of 
lung cancer. Moreover, perihilar mass with 
peribronchial compression and obstruction is the 
most common presenting symptom.6
To diagnose lung cancer, there are several 
diagnostic methods which may be used. First, 
clinical history and recognizing the typical, 
non-specific signs and symptoms of lung 
cancer, is needed. Then, further evaluation 
of the risk factors such as age, tobacco use, 
family history of cancer (especially lung cancer 
or oropharyngeal cancers) and exposure to 
asbestos. Next, the patient should be referred 
to a multidisciplinary team for diagnosis and 
evaluation. The patient will undergo a chest 
radiograph and Computed Tomography (CT) 
scan for diagnosing and staging of lung cancer 
if there is a suspicion of malignancy. Positron 
Emission Tomography (PET)-scan can be an 
additional combination tool to CT-scan, to 
diagnose and characterize the primary nodule, 
stage, and to treat lung cancer. Since surgery is 
the best treatment option, especially for patient 
in the early stage, preoperative evaluation may 
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be needed for lung cancer patients. Patients 
will have his/her cardiovascular risk quantified 
and their lung function assessed by using the 
Thoracic Revised Cardiac Risk Index (ThRCRI) 
and spirometry, respectiely. Sputum cytology 
testing, tumor marker evaluation, and biopsy 
by using Transbronchial Needle Aspiration 
(TBNA), Endobronchial Ultrasound (EBUS) 
with Fine-Needle Aspiration (FNA), Endoscopic 
Ultrasound (EUS) and transthoracic FNA or 
mediastinoscopy is also be necessary for the 
diagnosis and treatment evaluation.7
There are two types of staging in lung 
cancer, pathological/surgical and clinical 
staging. Pathologic staging has been mentioned 
in the previous paragraph.8 The newest edition 
of clinical staging is the eighth revision and 
it will be implemented in January 2017 by 
The International Association for the Study of 
Lung Cancer (IASLC). Further clinical staging 
is classified based on size of Tumor, Nodes, 
Metastasis (TNM) Classification. From the state 
of T, N and M, lung cancer is further classfied 
into different stages and this affects the treatment 
and prognosis of disease.9
Management of lung cancer differs from one 
subtype to another. In stage I and II of the disease, 
surgery, especially lobectomy, is the treatment 
of choice. Patients with stage II and III NSCLC 
may be offered a two-drug combination adjuvant 
chemotherapy, preferably with cisplatin.10 In 
patients with locally advanced or stage III disease, 
surgery with lung-sparing and minimal invasive 
technique may be indicated; added by adjuvant 
or neoadjuvant chemotherapy to improve 
cure rates by killing the micrometastases. In 
addition, radiotherapy may also be used for 
preoperative chemoradiotherapy, concurrent 
chemoradiotherapy or induction therapy 
followed by high-dose radiotherapy in patients 
with inoperable stage III NSCLC.11 In managing 
patients with stage IV disease, there will be a 
discussion among the multidisciplinary tumour 
board to choose the best treatment option based 
on the cancer histology, molecular pathology, 
age, performance status (PS), comorbidities, 
and patient preferences. Several approaches to 
management in stage IV patients are smoking 
cessation due to interaction with systemic therapy; 
systemic therapy with platinum-based doublet 
(i.e. cisplatin/carboplatin and gemcitabine/
taxanes/pemetrexed) as the first line, especially if 
the patient has PS 0-2; Tyrosine Kinase Inhibitors 
(TKIs), especially in patients with a mutation or 
rearrangement in the Epidermal Growth Factor 
Receptor (EGFR) or Anaplastic Lymphoma 
Kinase (ALK); and radiotherapy or surgery in 
patient with oligometastatic NSCLC.12 Recent 
advances also highlight the usage of antibodies 
to Vascular Endothelial Growth Factor (VEGF) 
such as Bevacizumab.13
RECEPTOR TYROSINE KINASE (RTK)
Receptor tyrosine kinase is one of cell 
surface receptors, which play a key role in cell 
proliferation and differentiation, cell survival 
and metabolism, cell migration and cell cycle 
control. There are 20 subfamilies of RTK with 
58 types in total, however, all of them havea 
similar configuration which consists of a ligand-
binding region, a single transmembrane helix, 
and a cytoplasmic region. The carboxy (C-) 
terminal and juxtamembrane regions of receptor 
tyrosin kinase may be found in the cytoplasmic 
region. During inactive periods, RTKs will form 
monomers or oligomers. When there is a growth 
factor or ligand binding, the receptors will undergo 
auto-phosphorylation, creating an activated 
kinase and phosphotyrosine-based binding site 
That can recruit Src homology-2 (SH2) and 
phosphotyrosine-binding (PTB) domains from 
the cytoplasm. Next, the RTK’active’ dimer or 
oligomers may further initiate the recruitment of 
other downstream signaling molecules. Being an 
‘active’ receptor, RTKs will lead to a subsequent 
activation of downstream a signalling pathway. 
Figure 1. Schematic diagram depicting the process of RTK 
activation. Firstly, the ligand will bind to an inactive RTK 
receptor and the dimerization process begin. Then, auto-
phosphorylation of the tyrosine residues occur (third part) and 
the phosphorylated RTKs may attract intracellular proteins 
for further activation of the signaling cascades.16
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Some of the pathways which may be involved are 
the mitogen-activated protein kinase (MAPK), 
phosphatidylinositol 3-kinase (PI3K), protein 
kinase C and GTPases (e.g. Ras and Rho). All 
of these signalling cascades leads to a specific 
function of the cell.14,15
EPIDERMAL GROWTH FACTOR RECEPTOR 
Epidermal Growth Factor Receptor (EGFR) 
is a protein which belongs to the ErbB receptor 
tyrosine kinases’ family along with HER2/c-neu 
(ERBB2), HER3 (ERBB3) and HER4 (ERBB4). 
This transmembrane receptor, also called as 
ERBB, ERBB1, and HER1, is encoded by the 
EGFR gene located on the short arm (p) of 
chromosome 7 position 12 (chr band 7p12.1), 
base pair 55,019,031 to 55,207,337 with ~2115 
nucleotides length analyzed. Based on high-
resolution X-ray crystal analysis, there are two 
ligand binding domain (domains I and III) and 
two cysteine rich domains (domain II and IV) in 
the EGFR family members which may be used 
in various extracellular or intracellular signalling 
pathways.17,18 To activate this receptor, there are 
a lot of ligands in this pathways, including the 
epidermal growth factor (EGF), betacellulin, 
amphiregulin, epigen, epidregulin and heparin 
binding EGF-like growth factors. The binding 
of these ligands will change the conformation of 
the receptor, leading to dimerization and auto-
phosphorylation of tyrosine in the intracellular 
domain. Then, auto-phosphorylated intracellular 
tyrosine residues will regulate the activation 
of downstream proteins and promote nucleus 
signal transduction.18 Some of the downstream 
target of EGFR are PI3K, RAS, mammalian 
target of rapamycin (mTOR), mitogen-activated 
protein kinase (MAPK), Janus Kinase (JAK), 
extracellular signal-regulated kinase (ERK), 
signal transducer and activator of transcription 
(STAT) signalling pathways.17 Moreover, 
activated EGFR also shown to have function 
in regulating the process of transcription, DNA 
synthesis and repair.19
Since the development EGFR-TKI was 
found found to be useful in treating NSCLC, 
the mutation status of EGFR has become more 
and more important. Mutation of EGFR will 
lead to NSCLC by increasing EGFR expression, 
enhancing ligand production and activating 
the mutation  of EGFR (exon 18-21 especially 
exon 19 deletion, exon 21 L858R substitution, 
exon 18 G719X missense mutation as the 
most common mutation) in malignant cell.5,13 
Upregulation of EGFR pathways will activate 
downstream proto-oncogene such as RAS and 
RAF, resulting in activation of other signaling 
pathway, tumor growth and proliferation.5 Study 
done by Nakamura et al.20 showed that there 
may be an association between mutation status 
of EGFR and volume doubling time (VDT) of 
adenocarcinoma. People with mutant EGFR had 
a longer VDT and this mutation may lead to a 
better patient prognosis. Other common mutation 
in EGFR is a point mutation in exon 20 of T790M 
which has an association with resistance to 
tyrosine kinase inhibitor. Research done by Costa 
et al.21 showed that patients with the T790M 
mutation had a shorter progression free survival 
(9.7 months vs 15.8 months in patients with no 
mutation) during treatment with erlotinib.
TYROSIN KINASE INHIBITORS 
Tyrosine kinase inhibitors (TKIs) have made 
a breakthrough in lung cancer management. 
Previously, some patient groups, especially the 
elderly who were diagnosed with lung cancer, 
had a poor prognosis and high incidence of death 
due to their inability to receive treatments such as 
operations or cytotoxic agents which have a lot 
of side effects. However, as the development of 
medicine continued, in this TKI era, even patients 
with poor PS but positive EGFR mutation can 
receive therapy to extend their life. Chen et al.22 
showed that elderly patients with positive EGFR 
mutation have significantly better overall survival 
compared to the wild type patients (13.2 vs 4.9 
months, p=0.003). Patients treated with erlotinib, 
a TKI, also had longer median progression-free 
survival than those by chemotherapy (13.1 [95% 
CI 10.58-16.53] vs 4.6 months [95% CI 4.21-
5.42] respectively) as shown in a study by Zhou 
et al.23 These result indicate that positive EGFR 
mutation status and use of TKIs may reverse the 
patient’s poor prognosis.
The first ever recognition of TKIs’ usage 
began in 2004, where a group of researchers found 
that a small group of patients who responded 
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to Gefitinib had distinct characteristics. These 
groups were those of Asian ethnicity, females, 
adenocarcinoma and never smoking status. Since 
then, trials were done and Gefitinib became 
the pioneer in treating EGFR-mutated NSCLC 
patients after publication of the Iressa Pan-Asia 
Study (IPASS). In that study, Gefitinib exhibited 
a superiority on progression-free suvival and 
overall response rate to Carboplatin/Paclitaxel. 
Then, other TKIs such as erlotinib, emerged and 
TKIs become one of the treatment option in lung 
cancer.24
Unfortunately, as time goes by, resistance was 
developed following one or two years treatment 
with first generation TKIs. The emerging of 
resistance towards TKIs were due to several 
mechanisms, one of which is rapid changes of 
cancer cells’ genome. Moreover, three pathways 
were responsible in acquiring resistance towards 
EGFR TKIs in lung cancer: 1) Growth factor 
receptor activation, 2) EGFR related protein and 
ligands activation, and 3) downstream signaling 
molecules activation. One of the most widely 
study mechanism was related to T790M, where 
this mutation may reduce the affinity of TKI 
towards EGFR and resistance occured. Other 
examples are HER2 amplification, expression of 
integrinβ1, altered expression B-cell lymphoma 
2 (Bcl2), Bcl2 interacting apoptosis mediator of 
cell death (BIM), p53 and nuclear-factor-kappa 
B (NF-kB) which related to apoptosis.24,25
In order to fight the evolution of this new 
subtype of lung cancer, the second generation 
of lung cancer medication was developed. This 
second generation has a better efficacy against 
the variation of an EGFR oncogene (such as the 
mutated EGFR-L858R/T790M). Afatinib and 
dacromitinib as some example of the newest 
market available generation may have a better 
suppression towards tyrosine kinase receptor 
by preventing the dimerization which promote 
receptors’ activity.26 The third generation (e.g. 
osimertinib and rociletinib) also emerge to 
accommodate neediness of competitive inhibition 
towards T790M mutant kinases.24 Since only first 
and second generation are available on market, 
further explanation will focus more on Gefitinib, 
Erlotinib and Afatinib. The comparison between 
those drugs can be seen in Table 1.
In general, Gefitinib, Erlotinib and Afatinib 
are oral medications which may inhibit EGFR 
tyrosine kinase, but only Afatinib can inhibit 
the receptor irreversibly. In terms of efficacy 
and side effects, all TKIs had a better efficacy 
compared with chemotherapy and shared almost 
similar types of side effects such as skin or 
gastrointestinal problems.26-34
In general, there are three TKIs: gefitinib, 
erlotinib, and afatinib as oral targeted agent 
which inhibit EGFR tyrosine kinase, however 
only afatinib can inhibits the receptor irreversibly. 
In term of efficacy, all TKIs had a significant 
response rate and progression free survival 
compared to chemotherapy in patients with 
EGFR mutation advanced/metastatic non small 
lung cancer and shared comparable side effects 
such as skin or gastrointestinal problem based 
on many large clinical trial.26-34
Mok et al.35 reported a phase 3, multicenter, 
randomized, open-label, paralled-group IPASS 
(Iressa Pan Asia) study that first-line gefitinib is 
more superior to carboplatin-paclitaxel for the 
treatment of clinically selected patients in east 
asia who had EGFR mutated advanced non-small 
cell lung cancer in terms of progression free 
survival (9.5 vs 6.3 months; HR 0.48, 95% CI: 
0.36-0.64; p<0.001) and response rate (71.2% 
vs 47.3%; p<0.001). In Japan, Mitsudomi et al.36 
also reported an open label phase 3 WJTOG3405 
study that gefitinib has longer progression free 
survival (9.2 months; 95% CI: 8.0-13.9 vs 6.3 
months; 95% CI 5.8-7.8; HR 0.489; 95% CI 
0.336-0.710; log rank p<0.001) in patients 
with lung cancer who are selected by EGFR 
mutations compared to cisplatin plus docetaxel 
significantly.
In China, Zhou et al.37 reported a multicentre, 
open label, randomised, phase 3 first-line 
treatment for patients with advanced EGFR 
mutation-positive non-small cell lung cancer 
OPTIMAL, CTONG-0820 study that median 
progression free survival of erlotinib-treated 
patients was significantly longer than in those 
on gemcitabine plus carboplatin (13.1 months; 
95% CI: 10.58-16.53 vs 4.6 months; 95% 
CI 4.21-5.24; HR 0.16; 95% CI 0.10-0.26; 
p<0.0001). In Europe, Rossel et al.38 also 
reported a multicentre, open-label, randomised 
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phase 3 European patients with advanced EGFR 
mutation-positive non-small cell lung cancer 
(EURTAC) trial that median progression free 
survival of erlotinib group was 9.7 months (95% 
CI: 8.4-12.3) compared with 5.2 months (95% 
CI: 4.5-5.8) standard chemotherapy cisplatin plus 
docetaxel group (HR 0.37; 95% CI: 0.25-0.54; 
p<0.0001).
Sequist et al.39 reported phase III of afatinib 
or cisplatin plus pemetrexed in patients with 
metastatic lung adenocarcinoma with EGFR 
mutations LUX-Lung 3 study that median 
progression free survival among those with 
exon 19 deletions and L858R EGFR mutations 
was 13.6 months for afatinib and 6.9 months 
for chemotherapy (HR 0.47; 95% CI 0.34-
0.65; p=0.001). Wu et al.40 also reported an 
open-label, randomised phase 3 trial of LUX-
Lung 6 that median progression free survival 
was significantly longer in the afatinib group 
(11.0 months; 95% CI: 9.7-13.7) than in the 
gemcitabine and cisplatin group (5.6 months; 
95% CI: 5.1-6.7; HR 0.28; 95% CI: 0.20-0.39). 
None of gefitinib and erlotinib demonstrated 
longer overall survival compared to standard 
chemotherapy. Yang JC et al.41 performed 
analysis of overall survival data from two 
randomised, phase 3 trials (LUX-Lung 3 and 
LUNG-Lux 6)) that showed eventhough none 
of both trial there were no significant benefit in 
overall survival, however in preplanned analysis, 
overall survival was significantly longer for 
patients with del 19 positive tumours in the 
afatinib group than in the chemotherapy group 
Table 1. Comparison between Gefitinib, Erlotinib, and Afatinib
Drugs Mechanism of Action Administration Efficacy Side Effects Price
Gefitinib Reversible inhibition 
of EGFR tyrosine 
kinase by competing 
with adenosine 
triphosphate at 
EGFR kinase binding 
sites. Then, EGFR 
signal transduction 
will be blocked.
Oral, tablet 250 
mg.
As the first line treatment 
to EGFR mutated 
patients, Gefitinib 
had a better median 
progression free 
survival compared to 
platinum-based doublet 
chemotherapy (10 
months vs 5-6 months). 
No significant difference 
in overall survival.












54 USD  per 
tablet 250 
mg.
Erlotinib Competitive inhibitor 
at ATP-binding 
pocket in intracellular 
domain of EGFR 
(same mechanism 
with Gefitinib).
Oral, tablet 25 
mg, 100 mg 
and 150 mg.
Compared to docetaxel/
pemetrexed, erlotinib had 
0.71 hazard ratio (0.13 
to 3.97) in patient with 
positive EGFR mutation. 
Moreover, longer median 
overall survival also 
observed in comparison 
with best supportive care 
patients (10.9 and 8.3 
months).




Mild to moderate 
rash, diarrhea, 
and  asymptomatic 
hypertransaminasemia.  
IDR 900,000 
or 60 USD 
per tablet 
150 mg.
Afatinib Irreversible binding 
of EGFR, inactivate 
dimerization process 
that promote the 
activity of tyrosine 
kinase receptor. 
Moreover, afatinib 
may inhibit enzymatic 
activity of wild-type 
EGFR, HER2, EGFR 
L858R and T790M 
mutant.
Oral, tablet 20 
mg, 30 mg and 
40 mg.
Compared with Cisplatin 
+ Pemetrexed, Afatinib 
had a superiority in 
terms of progression 
free survival and overall 
survival with 11.1 vs 
6.9 months and 31.6 
vs 28.2 months (HR: 
0.58, p=0.0004 and 
0.78, p=0.1) respectively  
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in both trials. In LUX-Lung 3, median overall 
survival was 33.3 months (95% CI: 26.8-41.5) 
in the afatinib group versus 21.1 months (95% 
CI: 16.3-30.7) in the chemotherapy cisplatin plus 
pemetrexed group (HR 0.54; 95% CI: 0.36-0.79; 
p = 0.0015). in LUX-Lung 6, median overall 
survival was 31.4 months (95% CI: 24.2-35.3) 
in the afatinib group versus 18.4 months (95% 
CI: 14.6-25.6) in the chemotherapy cisplatin plus 
gemcitabine group (HR 0.64; 95% CI: 0.44-0.94; 
p=0.0023).
Based on many clinical trials, in patients with 
advanced/metastatic non-small cell lung cancer 
when EGFR mutations are diagnosed in the first 
line setting, we have three options to administer 
EGFR TKIs: the first generation TKIs: Gefitinib 
and Erlotinib, and the second generation TKI: 
Afatinib. The question is which parameters 
should be taken into consideration regarding the 
choice of EGFR TKIs?
Park et al.42 performed a phase 2b, open-
label, randomised controlled trial afatinib versus 
gefitinib as first-line treatment of patients with 
EGFR mutation-positive non-small cell lung 
cancer (LUX-Lung 7). According to Park et 
al.42, LUX-Lung 7 is the first prospective head-
to-head trial to assess an irreversible EGFR TKI 
afatinib and a reversible EGFR TKI gefitinib, 
as first-line treatment of patients with EGFR 
mutation-positive non-small cell lung cancer in 
both Asians and non-Asian patients. Although it 
was an extrapolatory trial, the data indicated that 
afatinib might offer improved progression free 
survival compared with gefitinib. Progression 
free survival by blinded independent assessment 
was significantly longer with afatinib (11.0 
months; 95% CI: 10.6-12.9) versus gefitinib 
(10.9 months; 95% CI: 9.1-11.5).
The progression free survival curves 
seperated more substantially with time, starting 
at the median. This phenomenon might reflect 
the broader and more durable inhibitory profile 
of afatinib and its potential to delay possible 
resistance mechanism when compared with 
gefitinib.
The proportion of patients who achieved 
an objective tumour response was significantly 
higher with afatinib (70%) than with gefitinib 
Figure 2. Progression free survival of afatinib vs gefitinib by independent review.42 (Published under 
permission from original article entitled “Afatinib versus gefitinib as first-line treatment of patients with EGFR 
mutation-positive non-small-cell lung cancer (LUX-Lung 7): A phase 2B, open-label, randomised controlled 
trial”, published in Lancet Oncology 2016).
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(56%) by independent review (OR: 1.87; 95% 
CI: 1.18-2.99) and a longer median duration of 
response for patients treated with afatinib than 
gefitinib (10.1 months vs 8.4 moths).42 Peled43, 
Head of the Thoracic Cancer unit, Davidoff 
Cancer Center, Petah tikva, Israel recommended 
that in daily clinical practice, we take into 
account the type of the mutation, age, physical 
appearance of the patient, the side effects of 
TKIs, and comorbidity. If the patient is an old 
lady with many comorbidities, afatinib would not 
be the first choice, but a younger or middle-aged 
person with Exon 19 mutations can get benefit 
from afatinib. Afatinib also covers uncommon 
mutation, especially those in exon 18. Another 
consideration is brain metastases. Afatinib 
shows a favourable response rate with regard to 
brain lesions, eventhough the other TKIs elicit 
brain responses too. As the EGFR TKIs showed 
comparable progression free survival based 
on many trials, toxicity is one of the selection 
criteria. Diarrhea tends to occur more frequently 
with afatinib, as well as nail abnormalities, 
which can become a significant burden for 
many patients, forcing the doctor to decrease 
the afatinib dose. Eventhough dose reductions 
occured more often with afatinib than with 
gefitinib due to adverse events, however afatinib 
still preserved efficacy with dose reductions.
AFATINIB IN INDONESIA AND LESSON 
LEARNED
The fight against cancer in Indonesia 
started in the early 1920s during the Dutch 
Colonial Government with the Institution for 
Cancer Control. However, during the Japanese 
Colonization, this institution was closed and re-
built again in 1962 under the name of The Cancer 
Control Foundation. Since then, many efforts 
have been done to handle the cancer problems 
such as establishment of  Dharmais Cancer 
Center and cancer data collection.44 However, 
before the National  Health Insurance/Jaminan 
Kesehatan National (JKN) was implemented, 
cancer was  a huge problem, especially due to 
the lack of funds.45
Since the era of JKN, cancer patients have 
a better/longer chance of survival. Under the 
principle of social insurance and equality of 
services, JKN aims to ensure health care coverage 
of every Indonesia citizen.46 This includes 
services such as accomodation, diagnostic 
procedures, laboratory examinations, and other 
procedures related to cancer management.47 
Regarding cancer treatment in patients with 
positive EGFR mutation, first line Gefitinib 
and Erlotinib is covered by JKN and may 
be used as one of the treatment modalities. 
However, Afatinib in JKN is yet to be free of 
charge, yet it can be used as first line treatment 
options in EGFR mutation positive NSCLC 
management.43,48
CONCLUSION
Lung cancer is an iceberg phenomenon, 
where even with proper cancer management, 
high incidence and rate of mortality are still 
the norm. One of the recent advances in cancer 
management is the development of second 
generation TKIs, especially Afatinib as the 
newest available drug. This drug inhibits EGFR 
irreversibly compared with fisrt generation TKIs, 
Gefitinib and Erlotinib. Thus, Afatinib may be an 
alternative drug with a superior effect in patients 
with mutated EGFR. To be free of charge, this 
drug should be registered to JKN’s national 
formulary. Moreover, further research is needed, 
regarding the efficacy and adverse effects in the 
Indonesian population.
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